Realizing Effectiveness Across Continents With Hydroxyurea

Summary

REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs.

Timeline

Start

2023-10-27

Primary completion

2027-10-04

Completion

2033-10-04

Publications

• Backeljauw P, Tomlinson G, Smart LR, Tshilolo L, Williams TN, Santos B, Olupot-Olupot P, Stuber S, Lane A, Latham T, Ware RE. Growth and puberty in African children with sickle cell anemia treated with hydroxyurea. Blood Adv. 2026 Jul 14;10(13):4483-4494. doi: 10.1182/bloodadvances.2025019511.

Drugs

Indications